Fig. 6: Tumor Immune Infiltration and EGFR/PTEN Mutation Status Independently Predict OS Risk in Anti-PD-L1 Treated GBM Patients. | Nature Communications

Fig. 6: Tumor Immune Infiltration and EGFR/PTEN Mutation Status Independently Predict OS Risk in Anti-PD-L1 Treated GBM Patients.

From: Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a single arm prospective phase I/II trial

Fig. 6

A Multivariate hazard ratio analysis was performed using univariate features (high transcriptome-based Immune Score (n = 19) and EGFR mutation status (n = 4)) identified in this study, as well as, known GBM prognostic and predictive variables (MGMT methylation (n = 9); KPS - Kanofsky Performance Score (n = 31); Age (n = 31); Male (n = 21); STR - Subtotal Resection (n = 6)) (n = 31). Line plots are presented as HR + /- 95% CI. P-values are provided by Wald test. B Graphical image of study results showing the cancer cell intrinsic (differential gene expression of markers associated with activated dendritic cells, M1 macrophages, helper T cells, cytolytic markers and PTEN/EGFR mutation status) and gut microbiome features associated with longer mOS following anti-PD-L1 treatment. Created in BioRender. Woodman, S. (2024) https://BioRender.com/b92g788.

Back to article page